Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction
Recruitment status was Active, not recruiting
The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.
|Study Design:||Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Recombinant hCG (Ovidrel) Vesrus Urinary hCG (Pregnyl) for Ovulation Induction in Normal Responders|
- Level of hCG on day of oocyte retrieval
- Biochemical pregnancy per embryo transfer
- Clinical pregnancy per embryo transfer
- Ongoing pregnancy per embryo transfer
|Study Start Date:||June 2004|
|Estimated Study Completion Date:||December 2006|
Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte maturation and to trigger ovulation in assisted conception. Recombinant technology has allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this would allow the safe subcutaneous administration of a compound with less batch-to-batch variation. This study will investigate the effectiveness of the recombinant hCG compared to the currently used urinary hCG.